Irma Airoldi

List of Publications by Year
in descending order

58 papers	2,631 citations	147566 31 h-index	182168 51 g-index
59 all docs	59 docs citations	59 times ranked	4121 citing authors

#	Article	IF	Citations
1	Î³Î´ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-Î±Î²+/CD19+ lymphocytes. Blood, 2015, 125, 2349-2358.	0.6	224
2	Downregulation and/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma. Neoplasia, 2004, 6, 558-568.	2.3	216
3	IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget, 2015, 6, 43267-43280.	0.8	115
4	Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood, 2005, 106, 3846-3853.	0.6	110
5	Hypoxia-inducible factor (HIF)-1Î± suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia, 2013, 27, 1697-1706.	3.3	104
6	Expression and Function of IL-12 and IL-18 Receptors on Human Tonsillar B Cells. Journal of Immunology, 2000, 165, 6880-6888.	0.4	103
7	Stromal Cell-Derived Factor-1 as a Chemoattractant for Follicular Center Lymphoma B Cells. Journal of the National Cancer Institute, 2000, 92, 628-635.	3.0	92
8	Interleukin-27 Acts as Multifunctional Antitumor Agent in Multiple Myeloma. Clinical Cancer Research, 2010, 16, 4188-4197.	3.2	88
9	Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3996-4001.	3.3	83
10	Mechanisms of immune evasion of human neuroblastoma. Cancer Letters, 2005, 228, 155-161.	3.2	76
11	Zoledronic acid boosts Î³Î´ T-cell activity in children receiving Î±Î²⁺T and CD19⁺cell-depleted grafts from an HLA-haplo-identical donor. OncoImmunology, 2017, 6, e1216291.	2.1	76
12	Mda-9/Syntenin Is Expressed in Uveal Melanoma and Correlates with Metastatic Progression. PLoS ONE, 2012, 7, e29989.	1.1	64
13	Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia, 2011, 25, 1815-1824.	3.3	59
14	CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunology, Immunotherapy, 2008, 57, 541-548.	2.0	50
15	Interleukin-27 Inhibits the Growth of Pediatric Acute Myeloid Leukemia in NOD/SCID/Il2rgâˆ’/âˆ’ Mice. Clinical Cancer Research, 2012, 18, 1630-1640.	3.2	50
16	The antitumor potential of Interleukin-27 in prostate cancer. Oncotarget, 2014, 5, 10332-10341.	0.8	49
17	SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis. Oncotarget, 2016, 7, 12372-12385.	0.8	49
18	Immunogenicity of Human Neuroblastoma. Annals of the New York Academy of Sciences, 2004, 1028, 69-80.	1.8	48

#	Article	IF	Citations
19	Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. Leukemia, 2012, 26, 1365-1374.	3.3	48
20	Differential DNA binding properties of three human homeodomain proteins. Nucleic Acids Research, 1992, 20, 4465-4472.	6.5	47
21	CXCL12 Does Not Attract CXCR4+ Human Metastatic Neuroblastoma Cells: Clinical Implications. Clinical Cancer Research, 2006, 12, 77-82.	3.2	47
22	Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. Blood, 2010, 116, 3887-3898.	0.6	46
23	Interleukin-30 Expression in Prostate Cancer and Its Draining Lymph Nodes Correlates with Advanced Grade and Stage. Clinical Cancer Research, 2014, 20, 585-594.	3.2	46
24	IL-12 Can Target Human Lung Adenocarcinoma Cells and Normal Bronchial Epithelial Cells Surrounding Tumor Lesions. PLoS ONE, 2009, 4, e6119.	1.1	43
25	SNAI2/Slug gene is silenced in prostate cancer and regulates neuroendocrine differentiation, metastasis-suppressor and pluripotency gene expression. Oncotarget, 2015, 6, 17121-17134.	0.8	41
26	Interleukin-27 and interleukin-23 modulate human plasmacell functions. Journal of Leukocyte Biology, 2011, 89, 729-734.	1.5	40
27	The IL-18 Antagonist IL-18â€“Binding Protein Is Produced in the Human Ovarian Cancer Microenvironment. Clinical Cancer Research, 2013, 19, 4611-4620.	3.2	40
28	HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. Leukemia, 2011, 25, 527-537.	3.3	39
29	Constitutive expression of IL-12RÎ²2 on human multiple myeloma cells delineates a novel therapeutic target. Blood, 2008, 112, 750-759.	0.6	38
30	Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunology Letters, 2010, 133, 99-105.	1.1	34
31	Heterogeneous Expression of Interleukin-18 and Its Receptor in B-Cell Lymphoproliferative Disorders Deriving from Naive, Germinal Center, and Memory B Lymphocytes. Clinical Cancer Research, 2004, 10, 144-154.	3.2	32
32	Interleukin-30 Promotes Breast Cancer Growth and Progression. Cancer Research, 2016, 76, 6218-6229.	0.4	32
33	Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. British Journal of Cancer, 2003, 88, 1527-1536.	2.9	31
34	Interleukin-12 Receptor Î²2: From Cytokine Receptor to Gatekeeper Gene in Human B-Cell Malignancies. Journal of Clinical Oncology, 2009, 27, 4809-4816.	0.8	27
35	Regulation of angiostatic chemokines driven by IL-12 and IL-27 in human tumors. Journal of Leukocyte Biology, 2011, 90, 875-882.	1.5	27
36	Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer. Oncotarget, 2015, 6, 3694-3708.	0.8	27

#	Article	IF	Citations
37	Methylation of the IL-12RÎ²2 Gene as Novel Tumor Escape Mechanism for Pediatric B-Acute Lymphoblastic Leukemia Cells. Cancer Research, 2006, 66, 3978-3980.	0.4	26
38	Chemokines in neuroectodermal tumour progression and metastasis. Seminars in Cancer Biology, 2009, 19, 97-102.	4.3	26
39	Transcriptional Repression by the Human Homeobox Protein EVX1 in Transfected Mammalian Cells. Journal of Biological Chemistry, 1995, 270, 27695-27701.	1.6	23
40	New Perspectives for Melanoma Immunotherapy: Role of IL-12. Current Molecular Medicine, 2009, 9, 459-469.	0.6	20
41	IL-27 in Human Secondary Lymphoid Organs Attracts Myeloid Dendritic Cells and Impairs HLA Class Iâ€“Restricted Antigen Presentation. Journal of Immunology, 2014, 192, 2634-2642.	0.4	20
42	Human <scp>TCR</scp>Î³Î´⁺<scp>T</scp> cells represent a novel target for <scp>IL</scp>â€27 activity. European Journal of Immunology, 2012, 42, 1547-1552.	1.6	18
43	Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells. Clinical Cancer Research, 2011, 17, 6963-6970.	3.2	17
44	IL-27 Driven Upregulation of Surface HLA-E Expression on Monocytes Inhibits IFN-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi mathvariant="bold-italic">Î³</mml:mi></mml:mrow></mml:math>Release by Autologous NK Cells. Journal of Immunology Research, 2014, 2014, 1-7.	0.9	17
45	Anti-leukemic properties of IL-12, IL-23 and IL-27: Differences and similarities in the control of pediatric B acute lymphoblastic leukemia. Critical Reviews in Oncology/Hematology, 2012, 83, 310-318.	2.0	16
46	Cytokines and microRNA in pediatric B-acute lymphoblastic leukemia. Cytokine and Growth Factor Reviews, 2011, 22, 149-156.	3.2	15
47	EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells. Cellular Oncology (Dordrecht), 2017, 40, 483-496.	2.1	15
48	Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. Science Translational Medicine, 2018, 10, .	5.8	13
49	Targeting acute myeloid leukemia cells with cytokines. Journal of Leukocyte Biology, 2012, 92, 567-575.	1.5	12
50	The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1Â inhibition in myeloma cells. Haematologica, 2016, 101, e107-e110.	1.7	11
51	Engrafted maternal T cells in human severe combined immunodeficiency: Evidence for a T H2 phenotype and a potential role of apoptosis on the restriction of T-cell receptor variable Î² repertoire. Journal of Allergy and Clinical Immunology, 1998, 101, 131-134.	1.5	10
52	Ultrastructural and Functional Studies of the Interaction between IL-12 and IL-2 for the Generation of Lymphokine-Activated Killer Cells. Experimental Cell Research, 1999, 253, 440-453.	1.2	10
53	Absence of IL-12RÎ²2 in CD33+CD38+ pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RÎ³C-deficient mice. Leukemia, 2012, 26, 225-235.	3.3	7
54	IL12RB2 Polymorphisms correlate with risk of lung adenocarcinoma. Immunobiology, 2016, 221, 291-299.	0.8	6

#	Article	IF	Citations
55	Cytokines as Anti-Angiogenic Agents in Haematological Malignancies. Current Cancer Drug Targets, 2011, 11, 997-1004.	0.8	3
56	The enigmatic role of IL-12 in the pathogenesis of SjÃ¶gren's syndrome: Comment on article by Vosters J.L. et al. Arthritis and Rheumatism, 2010, 62, n/a-n/a.	6.7	1
57	Tumor Necrosis Factor (TNF) Enhances the Locomotion of Low-Density Human Tonsillar B Lymphocytes through the Selective Triggering of Type II Receptor. Annals of the New York Academy of Sciences, 1997, 815, 364-366.	1.8	0
58	The IL-12RÎ²2 gene functions as a tumor suppressor in human B cell malignancies. Journal of Clinical Investigation, 2014, 124, 2807-2807.	3.9	0